Inactive Instrument

DEINOVE

ALDEI

FR0010879056

Deinove Announces Consolidated Earnings Results for the Six Months Ended June 30, 2019

September 26, 2019 at 12:30 pm EDT

Deinove announced consolidated earnings results for the six months ended June 30, 2019. For the period, the company reported operating revenues of EUR 405,000 against EUR 715,000 a year ago. Operating loss was EUR 6,181,000 against EUR 4,355,000 a year ago. Consolidated loss was EUR 5,359,000 against EUR 3,735,000 a year ago.

Latest news about DEINOVE

Deinove SA(ENXTPA:ALDEI) dropped from Next Biotech Index	23-04-11	CI
Deinove: judicial liquidation, delisting in sight	23-01-25	CF
Court Reserves Decision On Deinove Receivership Proceedings	23-01-16	MT
Deinove SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-06	CI
Deinove SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-08	CI
Deinove SA Announces the Extension of Its Clinical Trial to Canada	22-04-07	CI
DEINOVE Appoints Michael MOUREZ as Chief Innovation Officer	22-03-17	CI
Deinove SA Announces A Favorable Opinion from the DSMBfor the Continuation of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile Infections	22-01-06	CI
Deinove SA announced that it expects to receive €10 million in funding from L1 Capital Pty. Limited	21-08-31	CI
Deinove Announces Collaboration with Max Mousseron Institute of Biomolecules and the LMP of the University of Montpellier	21-06-30	CI
Global markets live: Nestlé, Schindler, Credit Suisse	21-04-30
Deinove SA Announces Consolidated Financial Results for the Year Ended December 31, 2020	21-03-25	CI
Deinove Benefits from the Support of the French Government, Within the Framework of the France Relance Plan, to Accelerate the Development of New Antimicrobials	21-03-10	CI
Deinove SA Appoints Hervé Ansanay as Director	21-01-21	CI
Deinove SA Executive Changes	21-01-11	CI
Deinove SA Signs an Evaluation and Technology Development License with DSM	20-11-19	CI
Deinove Sa Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-30	CI
DEINOVE Pursues Phase II Clinical Trial of its Antibiotic Candidate DNV3837	20-07-15	CI
DEINOVE Appoints Alexis Rideau as CEO, Effective May 1, 2020	20-05-04	CI
Deinove Sa Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-29	CI
DEINOVE Announces the Official Launch of Luminity	20-04-23	CI
DEINOVE Provides Update on BIOME Oléoactif	20-03-18	CI
Deinove SA Expands its Range of Cosmetic Active Ingredients	20-02-19	CI
Sharon Laboratories Capitalizes on Deinove to Sustain Its Development Activities	20-02-06	CI
DEINOVE Announces the Inclusion of the First Patient in the Phase II Trial Testing DNV3837	20-01-27	CI

Chart DEINOVE

Duration

Period

More charts

Company Profile

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the "microbial dark matter". By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed. Nowadays, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the World primary emergencies.

Sector

Renewable Fuels

More about the company